A matched-pair analysis on survival and response rates between German and non-German cancer patients treated at a Comprehensive Cancer Center.
Cancer
Inequalities
Matched pair analysis
Migrants
Survival
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
30 Oct 2019
30 Oct 2019
Historique:
received:
30
01
2019
accepted:
02
10
2019
entrez:
1
11
2019
pubmed:
2
11
2019
medline:
9
4
2020
Statut:
epublish
Résumé
Research shows disparities in cancer outcomes by ethnicity or socio-economic status. Therefore, it is the aim of our study to perform a matched-pair analysis which compares the outcome of German and non-German (in the following described as 'foreign') cancer patients being treated at the Center for Integrated Oncology (CIO) Köln Bonn at the University Hospital of Bonn between January 2010 and June 2016. During this time, 6314 well-documented patients received a diagnosis of cancer. Out of these patients, 219 patients with foreign nationality could be matched to German patients based on diagnostic and demographic criteria and were included in the study. All of these 438 patients were well characterized concerning survival data (Overall survival, Progression-free survival and Time to progression) and response to treatment. No significant differences regarding the patients' survival and response rates were seen when all German and foreign patients were compared. A subgroup analysis of German and foreign patients with head and neck cancer revealed a significantly longer progression-free survival for the German patients. Differences in response to treatment could not be found in this subgroup analysis. In summary, no major differences in survival and response rates of German and foreign cancer patients were revealed in this study. Nevertheless, the differences in progression-free survival, which could be found in the subgroup analysis of patients with head and neck cancer, should lead to further research, especially evaluating the role of infectious diseases like human papillomavirus (HPV) and Epstein-Barr virus (EBV) on carcinogenesis and disease progression.
Sections du résumé
BACKGROUND
BACKGROUND
Research shows disparities in cancer outcomes by ethnicity or socio-economic status. Therefore, it is the aim of our study to perform a matched-pair analysis which compares the outcome of German and non-German (in the following described as 'foreign') cancer patients being treated at the Center for Integrated Oncology (CIO) Köln Bonn at the University Hospital of Bonn between January 2010 and June 2016.
METHODS
METHODS
During this time, 6314 well-documented patients received a diagnosis of cancer. Out of these patients, 219 patients with foreign nationality could be matched to German patients based on diagnostic and demographic criteria and were included in the study. All of these 438 patients were well characterized concerning survival data (Overall survival, Progression-free survival and Time to progression) and response to treatment.
RESULTS
RESULTS
No significant differences regarding the patients' survival and response rates were seen when all German and foreign patients were compared. A subgroup analysis of German and foreign patients with head and neck cancer revealed a significantly longer progression-free survival for the German patients. Differences in response to treatment could not be found in this subgroup analysis.
CONCLUSIONS
CONCLUSIONS
In summary, no major differences in survival and response rates of German and foreign cancer patients were revealed in this study. Nevertheless, the differences in progression-free survival, which could be found in the subgroup analysis of patients with head and neck cancer, should lead to further research, especially evaluating the role of infectious diseases like human papillomavirus (HPV) and Epstein-Barr virus (EBV) on carcinogenesis and disease progression.
Identifiants
pubmed: 31666035
doi: 10.1186/s12885-019-6241-9
pii: 10.1186/s12885-019-6241-9
pmc: PMC6822384
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1024Références
BMC Health Serv Res. 2017 Aug 23;17(1):588
pubmed: 28830423
J Behav Health. 2012;1(2):null
pubmed: 24496377
J Oral Pathol Med. 2008 Nov;37(10):593-8
pubmed: 19012621
BMC Public Health. 2010 Feb 24;10:92
pubmed: 20181232
J Environ Public Health. 2017;2017:2819372
pubmed: 28408935
Int J Cancer. 2010 Dec 15;127(12):2888-92
pubmed: 21351268
Int J Cancer. 2008 Jun 15;122(12):2656-64
pubmed: 18360824
Eur Arch Otorhinolaryngol. 2008 Jul;265 Suppl 1:S89-96
pubmed: 18193443
Oncotarget. 2017 Apr 18;8(16):27328-27338
pubmed: 28423694
Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):580-8
pubmed: 24521676
Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Nov;118(5):566-572.e1
pubmed: 25442493
Curr Opin Oncol. 2009 May;21(3):201-5
pubmed: 19370803
Eur J Cancer. 2010 Sep;46(14):2647-59
pubmed: 20843493
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Int J Cancer. 2014 Jun 15;134(12):2755-63
pubmed: 23913554
Anticancer Drugs. 2011 Aug;22(7):586-90
pubmed: 21403517
Health Expect. 2017 Oct;20(5):886-895
pubmed: 28261937
APMIS. 2010 Jun;118(6-7):510-9
pubmed: 20553531
Int J Cancer. 2014 Jun 15;134(12):2951-60
pubmed: 24259308
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Feb;59(2):151-2
pubmed: 26781779
Cancer Prev Res (Phila). 2009 Sep;2(9):782-91
pubmed: 19737985
J Laryngol Otol. 2016 May;130(S2):S9-S12
pubmed: 27841107
Semin Radiat Oncol. 2012 Jul;22(3):194-7
pubmed: 22687943
Cancer Causes Control. 2009 May;20(4):417-35
pubmed: 19002764
Int J Cancer. 2016 Oct 15;139(8):1696-702
pubmed: 27244597
Support Care Cancer. 2017 May;25(5):1391-1399
pubmed: 27942934
Soc Sci Med. 2015 Oct;142:9-18
pubmed: 26281022